DSC-127
feb 2013
Dermasciences-Diabetic foot ulcer Phase 3 trials of DSC-127, Nle3 A(l-7)
University of Southern California
A method for treating a subject that has suffered combined (i) exposure to total body ionizing irradiation and (ii) burns, comprising administering to the subject an amount effective to treat the radiation effects and/or the burn of a peptide comprising at least 5 amino acids of a peptide of SEQ ID NO: l (Asp- Arg-Nle-Tyr-Ile-His-Pro), or a pharmaceutical salt thereof.
WO-2012106427,
A method for treating diabetic foot ulcers, comprising administering to a human patient suffering from a diabetic foot ulcer an amount of a peptide of at least 5 contiguous amino acids of Nle3 A(l-7) effective to treat the diabetic foot ulcer
DSC127 is an analog of a naturally occurring peptide, Angiotensin. It has been shown to increase keratinocyte proliferation, increase extracellular matrix production, and increase vascularization. Additionally, histological examination has shown thatDSC127 accelerated collagen deposition six-fold. All these help to accelerate dermal tissue repair. One potential method of action is the up-regulation of mesenchymal stem cells (MSCs) at the site of injury. MSCs originate in the human embryo and are considered to be multipotent — a type of stem cell that has not yet adopted a specific cellular phenotype. Such cells have the ability to differentiate into various types of cells found within the human body, including fibroblasts, adipose cells, muscle cells, bone cells, and skin cells.
The patented amino acid peptide DSC127 optimizes the well published wound healing capabilities of Angiotensin while removing all blood pressure effects of the compound.
Derma Sciences, under license from the University of Southern California (USC), is developing DSC-127 (USB-001), a topical formulation of an angiotensin analog NorLeu3-A(1-7) that recruits mesenchymal stem cells to the sites of tissue injury, for the potential treatment of diabetic foot ulcer
Wound Repair and Regeneration
Volume 20, Issue 4, pages 482–490, July-August 2012
http://onlinelibrary.wiley.com/doi/10.1111/j.1524-475X.2012.00804.x/full
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....
